Skip to main content
SpringerLink
Log in

Relief is at hand for the majority of patients with gastro-oesophageal reflux disease

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49(5): 695–710

    Article  PubMed  CAS  Google Scholar 

  2. Cisapride: an alternative to other prokinetic and antisecretory agents in gastrointestinal motility disorders. Drug Ther Perspect 1994 May 30; 3(10): 1–4

    Article  Google Scholar 

  3. British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 28–39

  4. 1995 Physicians GenRx. St. Louis, Missouri: Mosby-Year Book, Inc., 1995

  5. Müossner J, Hüolscher AH, Herz R. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995 Jun; 9: 321–6

    Article  Google Scholar 

  6. Hassall E. Wrap session: is the Nissen slipping? Can medical treatment replace surgery for severe gastroesophageal reflux disease in children? Am J Gastroenterol 1995 Aug; 90: 1212–20

    PubMed  CAS  Google Scholar 

  7. Sontag SJ. Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 293–312

    Article  PubMed  CAS  Google Scholar 

  8. Robinson M, Lanza F, Lansoprazole Study Group. Lansoprazole for one year prevents recurrence of erosive reflux oesophagitis. Gastroenterology 1994; 106:A166

    Google Scholar 

  9. Dent J, Klinkenberg-Knol EC, Elm G, et al. Omeprazole in the long term management of patients with reflux oesophagitis refractory to histamine H2-antagonists. Gastroenterol Int 1988; 1 Suppl.: 847

    Google Scholar 

  10. Bate CM, Booth SN, Crowe JP. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995 Apr; 36: 492–8

    Article  PubMed  CAS  Google Scholar 

  11. FDA clears Prilosec for long-term care. Wall Street Journal 1995 Jun 27; B3

  12. Cost effectiveness of GORD therapy. Drug Ther Perspect 1993 Jul 19; 2(1): 14–16

    Article  Google Scholar 

  13. Bate CM, Green JRB, Taylor MD. Cost-effective prophylaxis against the recurrence of benign oesophageal stricture. Br J Med Econ 1995; 8: 97–109

    Google Scholar 

  14. Johnson NJ, Boyd EJS, Mills JG, et al. Acute treatment of reflux oesophagitis: a multicenter trial to compare 150mg ranitidine b.d. with 300mg ranitidine q.d.s. Aliment Pharmacol Ther 1989; 3: 259–66

    Article  CAS  Google Scholar 

  15. Kimmig JM. Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies. Aliment Pharmacol Ther 1995 Jun; 9: 281–6

    Article  PubMed  CAS  Google Scholar 

  16. Ching C-K, Lam S-K. Antacids: indications and limitations. Drugs 1994 Feb; 47(2): 305–17

    Article  PubMed  CAS  Google Scholar 

  17. Tytgat GNJ, Koelz H-R, Vosmaer GDC. Sucralfate maintenance therapy in reflux oesophagitis. Am J Gastroenterol 1995 Aug; 90: 1233-7

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Relief is at hand for the majority of patients with gastro-oesophageal reflux disease. Drugs Ther. Perspect 6, 11–13 (1995). https://doi.org/10.2165/00042310-199506090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199506090-00005

Search

Navigation